The Impact of Treatment Preferences in Second-Line Chemotherapy on the Prognosis of HER2-Negative Metastatic Breast Cancer

Por Mukai, Hirofumi, Hagiwara, Yasuhiro, Imi, Kentaro, Isaka, Hirotsugu, Watanabe, Kenichi, Matsuyama, Yutaka
Publicado no Oncology (2017)

Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC...

Por Hagiwara, Yasuhiro, Shiroiwa, Takeru, Shimozuma, Kojiro, Kawahara, Takuya, Uemura, Yukari, Watanabe, Takanori, Taira, Naruto, Fukuda, Takashi, Ohashi, Yasuo, Mukai, Hirofumi
Publicado no Pharmacoeconomics (2017)

Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

Por Shiroiwa, Takeru, Fukuda, Takashi, Shimozuma, Kojiro, Mouri, Mitsuko, Hagiwara, Yasuhiro, Kawahara, Takuya, Ohsumi, Shozo, Hozumi, Yasuo, Sagara, Yoshiaki, Ohashi, Yasuo, Mukai, Hirofumi
Publicado no BMC Cancer (2017)

Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST s...

Por Hagiwara, Yasuhiro, Ohashi, Yasuo, Okusaka, Takuji, Ueno, Hideki, Ioka, Tatsuya, Boku, Narikazu, Egawa, Shinichi, Hatori, Takashi, Furuse, Junji, Mizumoto, Kazuhiro, Ohkawa, Shinichi, Yamaguchi, Taketo, Yamao, Kenji, Funakoshi, Akihiro, Cheng, Ann-Lii, Kihara, Kiyohiro, Sato, Atsushi, Tanaka, Masao
Publicado no ESMO Open (2017)